New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 29, 2012
13:51 EDTOREX, ARNA, VVUSVIVUS drug's CV profile viewed positively by FDA, says Rodman & Renshaw
After attending an FDA panel hearing focused on the effects of anti-obesity drugs on cardiovascular systems, Rodman & Renshaw believes that the FDA and the panel are comfortable with the cardiovascular profile of VIVUS' drug, Qnexa. The firm indicates that it doesn't expect the agency to require additional cardiovascular tests before Qnexa is approved, and it reiterates an Outperform rating on VIVUS.
News For VVUS;ARNA;OREX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 3, 2015
06:30 EDTVVUSVIVUS price target lowered to $2.30 from $3 at WallachBeth
WallachBeth analyst Bob Ai lowered his price target for VIVUS for $2.30 after the company announced plans to cut its sales force by one-half, to 50, in order to achieve its new corporate goal of operating cash flow being neutral or positive by the end of 2016. This is not the best move for long-term shareholders, Ai tells investors in a research note. The sales force reduction may result in a significant sales decline, the analyst believes. He keeps a Hold rating on VIVUS.
July 30, 2015
19:08 EDTVVUSVIVUS announces restructuring plan, will reduce headcount
Subscribe for More Information
16:02 EDTVVUSVIVUS reports Q2 EPS (19c), consensus (24c)
Subscribe for More Information
July 29, 2015
08:22 EDTARNAArena Pharmaceuticals begins Phase 2 trial of candidate for autoimmune diseases
Subscribe for More Information
July 23, 2015
11:54 EDTOREXOptions with increasing call volume
Subscribe for More Information
July 21, 2015
15:42 EDTARNAArena Pharmaceuticals receives USPTO patent
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use